As previously suspected, this could argue for a defect in anti-TERT CD4+ response during melanoma progression [36] and may explain why in our analysis, patients with high CD4+ T cell estimates and increased TERT expression did not show a survival benefit. The gene discussed is TERT; the disease is melanoma.